Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults

Alzheimer's and Dementia

Volumn 8, Issue 6, 2012, Pages 520-527

  Paternicò, Donata ^a   Galluzzi, Samantha ^a   Drago, Valeria ^a   Bocchio Chiavetto, Luisella ^a   Zanardini, Roberta ^a   Pedrini, Laura ^a   Baronio, Manuela ^b   Amicucci, Giovanni ^b   Frisoni, Giovanni B ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b S Orsola Hospital   (Italy)

Author keywords

Age; Alzheimer's disease; Apolipoprotein E; Biomarkers; Cerebrospinal fluid; Healthy adult

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; FEMALE; GENOTYPE; GROUPS BY AGE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; TAU PROTEINS; YOUNG ADULT;

EID: 84867897154     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.10.003     Document Type: Article

References (43)

1. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria (review) Lancet Neurol 6 2007 734 746
2. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349
3. L. Glodzik-Sobanska, E. Pirraglia, M. Brys, S. de Santi, L. Mosconi, and K.E. Rich The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease Neurobiol Aging 306 2009 72 81
4. E.C. Petrie, D.J. Cross, D. Galasko, G.D. Schellenberg, M.A. Raskind, and E.R. Peskind Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings Arch Neurol 666 2009 32 37
5. D.J. Selkoe Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein J Alzheimers Dis 3 2001 75 80
6. H. Mori, K. Hosoda, E. Matsubara, T. Nakamoto, Y. Furiya, and R. Endoh Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau Neurosci Lett 186 1995 181 183
7. T. Grimmer, M. Riemenschneider, H. Förstl, G. Henriksen, W.E. Klunk, and C.A. Mathis Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 65 2009 927 934
8. C.L. Grady, J.V. Haxby, B. Horwitz, M. Sundaram, G. Berg, and M. Schapiro Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type J Clin Exp Neuropsychol 10 1988 576 596
9. J.C. Morris, and A.L. Price Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease J Mol Neurosci 17 2001 101 118
10. K.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, and P. Maruff Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain 130 2007 2837 2844
11. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
12. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
13. G. Li, I. Sokal, J.F. Quinn, J.B. Leverenz, M. Brodey, and G.D. Schellenberg CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 2007 631 639
14. M.A. Mintun, G.N. Larossa, Y.I. Sheline, C.S. Dence, S.Y. Lee, and R.H. Mach [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 67 2006 446 452
15. I. Skoog, P. Davidsson, O. Aevarsson, H. Vanderstichele, E. Vanmechelen, and K. Blennow Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds Dement Geriatr Cogn Disord 15 2003 169 176
16. E. Stomrud, O. Hansson, K. Blennow, L. Minthon, and E. Londos Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly Dement Geriatr Cogn Disord 24 2007 118 124
17. D.R. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women J Neurol Neurosurg Psychiatry 78 2007 461 464
18. A.D. Roses Apolipoprotein, E alleles as risk factors in Alzheimer's disease (review) Annu Rev Med 47 1996 387 400
19. P. Aksari, and G. Stoppe Risk factors in Alzheimer's dementia (review) Fortschr Neurol Psychiatr 64 1996 425 432
20. J. Popp, P. Lewczuk, I. Frommann, H. Kölsch, J. Kornhuber, and W. Maier Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype J Alzheimers Dis 22 2010 459 468
21. M. Sjögren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge, and C. Wikkelso Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values Clin Chem 47 2001 1776 1781
22. M. Shoji, M. Kanai, E. Matsubara, Y. Tomidokoro, M. Shizuka, and Y. Ikeda The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently Neurobiol Aging 22 2001 209 215
23. E.R. Peskind, G. Li, J. Shofer, J.F. Quinn, J.A. Kaye, and C.M. Clark Age and apolipoprotein E4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition Arch Neurol 63 2006 936 939
24. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, and E. Weiller The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 59 1998 22 33
25. M.F. Folstein, S.E. Folstein, and P.R. McHugh Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
26. J.E. Kang, M.M. Lim, R.J. Bateman, J.J. Lee, L.P. Smyth, and J.R. Cirrito Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle Science 326 2009 1005 1007
27. M. Ingelsson, Y. Shin, M.C. Irizarry, B.T. Hyman, L. Lilius, and C. Forsell Genotyping of apolipoprotein E: comparative evaluation of different protocols Curr Protoc Hum Genet 9 2003 Unit 9.14
28. S.S. Petanceska, V. Nagy, D. Frail, and S. Gandy Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain Exp Gerontol 35 2000 317 325
29. P. Schönknecht, J. Pantel, K. Klinga, M. Jensen, T. Hartmann, and B. Salbach Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease Neurosci Lett 307 2001 122 124
30. P. Gudmundsson, I. Skoog, M. Waern, K. Blennow, S. Pálsson, and L. Rosengren The relationship between cerebrospinal fluid biomarkers and depression in elderly women Am J Geriatr Psychiatry 15 2007 832 838
31. S Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-43.
32. M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsäter, and R. Anckarsäter Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid Int J Alzheimers Dis 2010 986310
33. R.D. Terry, R. DeTeresa, and L.A. Hansen Neocortical cell counts in normal human adult aging Ann Neurol 21 1987 530 539
34. K. Buerger, R. Zinkowski, S.J. Teipel, T. Tapiola, H. Arai, and K. Blennow Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 Arch Neurol 59 2002 1267 1272
35. V. Leinonen, A.M. Koivisto, S. Savolainen, J. Rummukainen, J.N. Tamminen, and T. Tillgren Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease Ann Neurol 68 2010 446 453
36. A.M. Fagan, D. Head, A.R. Shah, D. Marcus, M. Mintun, and J.C. Morris Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly Ann Neurol 65 2009 176 183
37. F. Panza, A. D'Introno, A.M. Colacicco, C. Capurso, S. Capurso, and P.G. Kehoe Vascular genetic factors and human longevity Mech Ageing Dev 125 2004 169 178
38. J.A. Prince, H. Zetterberg, N. Andreasen, J. Marcusson, and K. Blennow APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42 Neurology 62 2004 2116 2118
39. T. Sunderland, N. Mirza, K.T. Putnam, G. Linker, D. Bhupali, and R. Durham Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele Biol Psychiatry 56 2004 670 676
40. S. Vuletic, G. Li, E.R. Peskind, H. Kennedy, S.M. Marcovina, J.B. Leverenz, and E.C. Petrie Apolipoprotein E highly correlates with AβPP- and tau-related markers in human cerebrospinal fluid confounding factors influencing amyloid Beta concentration in cerebrospinal fluid J Alzheimers Dis 15 2008 409 417
41. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 6820 6825
42. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395.e6
43. N.A. Verwey, W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, and P.P. De Deyn A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 2009 235 240